Company profile
ALX Oncology Holdings Inc.
NASDAQ: ALXO · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
37DFH 39DQ 40GM 18SS 50
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ 3-yr revenue growth, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$101.7M
Employees
43
as of 2026-08-13
Market cap
$270.5M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02022
Net income-$101.7M-$101.7M2025
Operating income-$104.0M-$104.0M2025
Total assets$59.0M$59.0M2025
Liabilities$33.1M$33.1M2025
Equity$26.0M$26.0M2025
Revenue trend
FY2020 – FY2022 · USD
FY20
FY20
FY20
FY22
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ALX Oncology Holdings Inc.’s revenue?
ALX Oncology Holdings Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Zentalis Pharmaceuticals, Inc.40DEledon Pharmaceuticals, Inc.39DFulcrum Therapeutics, Inc.59CCytoDyn Inc.——Capricor Therapeutics, Inc.57CMinerva Neurosciences, Inc.38DNeighbors
San Mateo →Key facts
CEOJason Lettmann
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ALXO
Employees43
IPO date2020-07-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.